FilingSEC EDGAR8-K
Aptevo Therapeutics Announces Reduction in Infusion-Related Reactions for Mipletamig in AML
· SEC accepted
Filing content
Aptevo Therapeutics announced a significant reduction in infusion-related reactions for its AML drug candidate, mipletamig, through refined priming-dose regimens, strengthening its readiness for Phase 2 development.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…